Gao Ming, Zhou Qing
The Second School of Clinical Medicine, Southern Medical University, Guangzhou 510515, China.
Guangdong Lung Cancer Institute, Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, School of Medicine, South China University of Technology, Guangzhou 510080, China.
Zhongguo Fei Ai Za Zhi. 2020 Oct 20;23(10):866-874. doi: 10.3779/j.issn.1009-3419.2020.101.35. Epub 2020 Aug 17.
Lung cancer ranks first both in mobidity and motality in china and worldwild. Squamous cell lung carcinoma is distinguished from lung adenocarcinoma in diagnosis and treatment due to its unique clinical & pathological manifestations and gene mutation characteristics, as a result, it is also explored as a separate type in clinical researches. In addition to the clinical manifestations of elderly, central tumors, late staging at diagnosis, and multiple comorbidities, the lack of driver genes makes it nearly impossible for these patients to benefit from targeted therapy. However, the exploration of targeted therapy for lung squamous cell carcinoma has never stopped. Several new drugs including fibroblast growth factor receptor tyrosine kinase inhibitor and cyclin dependent kinase 4 and 6 inhibitors have been studied in multiple phase I studies specifically in patients with lung squamous cell carcinoma. However, with the development of immunotherapy, the characteristics such as complex gene mutation and high tumor mutation burden makes it possible for patients with squamous cell lung cancer to benefit from immunotherapy combined with chemotherapy. This review will provide an overview of the treatment progress in advanced squamous cell lung cancer including chemotherapy, targeted therapy and immunotherapy. .
肺癌在中国和全球的发病率和死亡率均位居首位。肺鳞状细胞癌因其独特的临床和病理表现以及基因突变特征，在诊断和治疗上有别于肺腺癌，因此在临床研究中也被作为一种单独的类型进行探索。除了具有老年、中央型肿瘤、诊断时分期较晚以及多种合并症等临床表现外，缺乏驱动基因使得这些患者几乎无法从靶向治疗中获益。然而，对肺鳞状细胞癌靶向治疗的探索从未停止。包括成纤维细胞生长因子受体酪氨酸激酶抑制剂以及细胞周期蛋白依赖性激酶4和6抑制剂在内的几种新药已在多项专门针对肺鳞状细胞癌患者的I期研究中进行了研究。然而，随着免疫疗法的发展，复杂的基因突变和高肿瘤突变负荷等特征使得肺鳞状细胞癌患者有可能从免疫疗法联合化疗中获益。本综述将概述晚期肺鳞状细胞癌在化疗、靶向治疗和免疫治疗方面的进展。
